- ICH GCP
- Registro de ensayos clínicos de EE. UU.
- Ensayo clínico NCT06208878
Un estudio de seguimiento a largo plazo de sujetos que recibieron terapias celulares CRISPR CAR T
Un estudio de seguimiento a largo plazo de sujetos con neoplasias malignas tratados con terapias celulares CRISPR CAR T
This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies
Descripción general del estudio
Estado
Condiciones
Intervención / Tratamiento
Descripción detallada
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Tipo de estudio
Inscripción (Estimado)
Contactos y Ubicaciones
Ubicaciones de estudio
-
-
-
Hamburg, Alemania, D-20246
- University Hospital Hamburg-Eppendorf
-
-
-
-
-
Melbourne, Australia
- Alfred Health
-
Nedlands, Australia, 6009
- Sir Charles Gairdner
-
Richmond, Australia
- Epworth Healthcare
-
-
New South Wales
-
Camperdown, New South Wales, Australia, 2050
- Royal Prince Alfred Hospital
-
-
Victoria
-
Melbourne, Victoria, Australia, 3000
- Peter MacCallum Cancer Center
-
-
-
-
Ontario
-
Toronto, Ontario, Canadá, M5G 2M9
- Princess Margaret
-
-
-
-
California
-
Duarte, California, Estados Unidos, 91010
- City of Hope
-
Los Angeles, California, Estados Unidos, 90048
- Cedars Sinai
-
Stanford, California, Estados Unidos, 94305
- Stanford
-
-
Connecticut
-
New Haven, Connecticut, Estados Unidos, 06510
- Yale New Haven Hospital
-
-
Georgia
-
Atlanta, Georgia, Estados Unidos, 30322
- Emory
-
-
Illinois
-
Chicago, Illinois, Estados Unidos, 60637
- University of Chicago
-
-
Kansas
-
Westwood, Kansas, Estados Unidos, 66205
- University of Kansas
-
-
Minnesota
-
Minneapolis, Minnesota, Estados Unidos, 55455
- University of Minnesota
-
-
Missouri
-
St Louis, Missouri, Estados Unidos, 63110
- Washington University Saint Louis
-
-
New York
-
New York, New York, Estados Unidos, 10065
- MSKCC
-
The Bronx, New York, Estados Unidos, 10467
- Montefiore Medical Center
-
-
Oregon
-
Portland, Oregon, Estados Unidos, 97239
- Oregon Health and Science University
-
-
Pennsylvania
-
Philadelphia, Pennsylvania, Estados Unidos, 19104
- University of Pennsylvania
-
-
Texas
-
Dallas, Texas, Estados Unidos, 75390
- UT Southwestern
-
Houston, Texas, Estados Unidos, 77030
- MD Anderson Cancer Center
-
San Antonio, Texas, Estados Unidos, 78229
- Methodist Hospital-Sarah Cannon
-
-
Utah
-
Salt Lake City, Utah, Estados Unidos, 84112
- University of Utah-Huntsman Cancer Institute
-
-
Criterios de participación
Criterio de elegibilidad
Edades elegibles para estudiar
Acepta Voluntarios Saludables
Géneros elegibles para el estudio
Método de muestreo
Población de estudio
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. Subjects who have completed the parent study for the protocol-defined duration, or who have discontinued the parent study early, or who are in secondary follow-up (follow up of subjects with progressive disease or who receive a subsequent line of anticancer therapy) in the parent study may enroll in this LTFU study. This will allow for collection of long-term efficacy data (as applicable) and safety data up to 15 years post-treatment with CRISPR CAR T cellular therapies.
Descripción
Inclusion Criteria:
- Able to understand and comply with protocol-required study procedures and voluntarily sign and date a written informed consent document.
- Must have received CRISPR CAR T cellular therapy.
Exclusion Criteria:
- There are no specific exclusion criteria.
Plan de estudios
¿Cómo está diseñado el estudio?
Detalles de diseño
- Modelos observacionales: COHORT
- Perspectivas temporales: PROSPECTIVE
Cohortes e Intervenciones
Grupo / Cohorte |
Intervención / Tratamiento |
|---|---|
|
Non Interventional
All subjects with hematological and solid malignancies who are enrolled in a parent study and were exposed to allogeneic CRISPR CAR T cellular therapy will be asked to participate in this long-term follow-up (LTFU) study. |
Safety and Efficacy Assessment |
¿Qué mide el estudio?
Medidas de resultado primarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The incidence of adverse events, serious adverse events and adverse events of special interest related to CRISPR CAR T cellular therapy treatment.
Periodo de tiempo: 15 years
|
The number and percentage of subjects with CRISPR CAR T cellular therapy related SAEs and AESIs will be summarized. |
15 years
|
Medidas de resultado secundarias
Medida de resultado |
Medida Descripción |
Periodo de tiempo |
|---|---|---|
|
The overall survival and duration of remission/response following CRISPR CAR T cellular therapy treatment
Periodo de tiempo: 15 years
|
Overall survival will be calculated as the time between the initial dose of CRISPR CAR T cellular therapy in the parent study and death due to any cause. Duration of remission/response will be calculated as the time between the first objective response to first disease progression or death due to any cause. |
15 years
|
Colaboradores e Investigadores
Patrocinador
Fechas de registro del estudio
Fechas importantes del estudio
Inicio del estudio (Actual)
Finalización primaria (Estimado)
Finalización del estudio (Estimado)
Fechas de registro del estudio
Enviado por primera vez
Primero enviado que cumplió con los criterios de control de calidad
Publicado por primera vez (Actual)
Actualizaciones de registros de estudio
Última actualización publicada (Actual)
Última actualización enviada que cumplió con los criterios de control de calidad
Última verificación
Más información
Términos relacionados con este estudio
Términos MeSH relevantes adicionales
Otros números de identificación del estudio
- CRSP-ONC-LTF
Información sobre medicamentos y dispositivos, documentos del estudio
Estudia un producto farmacéutico regulado por la FDA de EE. UU.
Estudia un producto de dispositivo regulado por la FDA de EE. UU.
Esta información se obtuvo directamente del sitio web clinicaltrials.gov sin cambios. Si tiene alguna solicitud para cambiar, eliminar o actualizar los detalles de su estudio, comuníquese con register@clinicaltrials.gov. Tan pronto como se implemente un cambio en clinicaltrials.gov, también se actualizará automáticamente en nuestro sitio web. .